Comparative Pharmacology
Head-to-head clinical analysis: EPINASTINE HYDROCHLORIDE versus ISOCLOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPINASTINE HYDROCHLORIDE versus ISOCLOR.
EPINASTINE HYDROCHLORIDE vs ISOCLOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective histamine H1-receptor antagonist. Inhibits histamine release from mast cells and basophils, and reduces chemotaxis and activation of eosinophils. Also suppresses cytokine production from T lymphocytes.
Chlorpheniramine is an antihistamine (H1-receptor antagonist) that blocks the action of histamine, reducing allergy symptoms. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors, causing vasoconstriction in the nasal mucosa.
For allergic rhinitis and urticaria: 10 mg twice daily orally (20 mg/day). For ophthalmic use: 1 drop in affected eye(s) twice daily of 0.05% solution.
Oral: 1 tablet (chlorpheniramine 4 mg / pseudoephedrine 60 mg) every 4-6 hours, not to exceed 4 tablets per 24 hours.
None Documented
None Documented
The terminal elimination half-life is approximately 5.7 to 9.2 hours in healthy adults. In elderly patients, the half-life may be prolonged due to reduced renal function. The half-life supports twice-daily dosing for most indications.
Approximately 2-4 hours in patients with normal renal function; prolonged to 8-12 hours in renal impairment (CrCl <30 mL/min).
Renal excretion accounts for approximately 39% of the administered dose, with about 28% as unchanged drug and 11% as metabolites. Fecal excretion is minimal at approximately 10%. Biliary excretion is not a significant route. Overall, renal clearance is the primary elimination pathway.
Primarily renal; approximately 60-70% of a dose excreted unchanged in urine within 24 hours. Biliary/fecal excretion accounts for <10%.
Category A/B
Category C
Antihistamine
Antihistamine/Decongestant Combination